1. Early treatment with combination of SS31 and entresto effectively preserved the heart function in doxorubicin-induced dilated cardiomyopathic rat
- Author
-
Yi-Ching Chu, Jiunn-Jye Sheu, John Y. Chiang, Hon-Kan Yip, Sarah Chua, Chi-Ruei Huang, Pei-Hsun Sung, and Jui-Ning Yeh
- Subjects
Cardiomyopathy, Dilated ,Male ,medicine.medical_specialty ,Dilated cardiomyopathy ,Inflammation ,RM1-950 ,medicine.disease_cause ,Entresto ,Ventricular Function, Left ,Time-to-Treatment ,Rats, Sprague-Dawley ,Angiotensin Receptor Antagonists ,Fibrosis ,Internal medicine ,medicine ,Pi ,Animals ,Doxorubicin ,Pharmacology ,Ejection fraction ,business.industry ,Aminobutyrates ,Biphenyl Compounds ,Stroke Volume ,General Medicine ,medicine.disease ,Rats ,Drug Combinations ,Oxidative Stress ,Endocrinology ,Treatment Outcome ,Apoptosis ,cardiovascular system ,Valsartan ,Drug Therapy, Combination ,Therapeutics. Pharmacology ,medicine.symptom ,business ,Oligopeptides ,Oxidative stress ,medicine.drug ,SS31 - Abstract
Background: This study tested the hypothesis that early administration of SS31 and entresto (En) was superior to either one alone on preserving the heart function in setting of dilated cardiomyopathy (DCM) induced by doxorubicin (Dox) [accumulated dosage of 12.5 mg/kg/administered by intraperitoneal (IP) at 4 separated time points within 20 days] in rat. Methods and results: Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60. By day 60, left-ventricular ejection-fraction (LVEF) was highest in group 1, lowest in group 2 and significantly higher in group 5 than in groups 3 and 4 (all p
- Published
- 2021